郭靜娟

JJ Kuo 2郭靜娟  研究員
生技與藥物研究所
Email: cckuo@nhri.edu.tw

 

EDUCATION

  • Ph.D., National Taiwan University, Taipei, Taiwan, 2001

PROFESSIONAL EXPERIENCES

  • Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health research Institutes, Miaoli, Taiwan (2022-now)
  • Associate Investigator, Institute of Biotechnology and Pharmaceutical Research, National Health research Institutes, Miaoli, Taiwan (2013-2021)
  • Associate Investigator, National Institute of Cancer Research, National Health research Institutes, Miaoli, Taiwan (2012-2013)
  • Assistant Investigator, National Institute of Cancer Research, National Health research Institutes, Miaoli, Taiwan (2007-2012)
  • Research Associate, National Institute of Cancer Research, National Health Research Institutes, Taipei, Taiwan. (2004-2007)
  • Post Doctoral Fellow, Division of Cancer Research, National Health Research Institutes, Taipei, Taiwan. (2001-2004)

RESEARCH INTERESTS

Novel oncotarget identification and validation, clinically relevant tumor models, experimental therapeutics, anticancer drug discovery, chemo/radio-resistance, precision medicine, translational research

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Ching-Chuan Kuo, a Doctor of Philosophy (Ph.D.), is now an Investigator at the Institute of Biotechnology and Pharmaceutical Research (IBPR), National Health Research Institutes (NHRI). Dr. Kuo received professional training in nutritional biochemistry and natural chemical chemistry during her doctoral studies. She obtained a Ph.D. from National Taiwan University in 2001, and then entered the Division of Cancer Research (now the National Institute of Cancer Research, NICR) of NHRI as a postdoctoral fellow, and began to build an academic career in experimental therapeutics of cancer. Dr. Kuo joined the NHRI faculty in October 2007 as an Assistant Investigator in NICR-NHRI. Dr. Kuo was promoted to an Associate Investigator in July 2012 and then moved to IBPR-NHRI in March 2013. From January 2022, Dr. Kuo was promoted to an Investigator. In the past few years, her major efforts have been divided into four parts: (1) novel target identification and validation (with a focus on the targets of immuno-oncology and cancer metabolism); (2) establishment of novel patient-derived cancer models for drug discovery, etiology studies, as well as precision medicine; (3) discovery of novel therapeutic agents and combination strategies for cancer therapy; and (4) investigation of novel chemo/radio-resistance mechanisms and reversal strategies. Dr. Kuo is a cancer biologist and pharmacologist with more than 20 years of experience in the fields of drug discovery and development, preclinical pharmacology, and experimental therapeutics of cancer research. To date, Dr. Kuo has published more than 95 SCI articles in the field and received two patents. In particular, four drug candidates from her participating development projects have received the Investigational New Drug (IND) approval by US-FDA and Taiwan FDA for clinical investigation.

PUBLICATIONS

  1. Yeh, T.-K., Song, J.-S., Chang, P.-W., Yu, J.-C., Chang, C.-H., Liao, F.-Y., Tien, Y.-W., Kuppusamy, R., Li, A.-S., Chen, C.-H., Chen, C.-W., Lin, L.-M., Chang, H.-H., Huang, C.-H., Yao, J.-Y., Wu, M.-H., Peng, Y.-H., Hsueh, C.-C., Hsiao, W.-C., Chen, P.-H., Lin, C.-Y., Hsieh, S.-H., Shih, C., Hung, M.-S.*, Wu, S.-Y.*, Kuo, C.-C.*, Ueng, S.-H.* Discovery and development of a novel N-(3-bromophenyl)-{[(phenylcarbamoyl)amino]methyl}-N-hydroxythiophene-2-carboximidamide indoleamine 2,3-dioxygenase inhibitor using knowledge-based drug design. European Journal of Medicinal Chemistry 2021 Dec 8; 229:114043 (Online ahead of print) (SCI; Category: Chemistry, Medicinal; Impact factor: 6.614; Ranking: 5/63, 7.9%, 2020 JCR) (*Corresponding author)
  2. Tang, Y.-C., Chang, H.-H., Chen, H.-H., Yao, J.-Y., Chen, Y.-T., Chuang, Y.-J., Chang, J.-Y., Kuo, C.-C.* A novel NRF2/ARE2 inhibitor gossypol induces cytotoxicity and sensitizes chemotherapy response in chemo-refractory cancer cells. Journal of Food and Drug Analysis 2021 Dec 14; 29(4):638-652 (SCI; Category: Pharmacology & Pharmacy; Impact factor: 6.079; Ranking: 34/275, 12.4%, 2020 JCR)(*Corresponding author)
  3. Lee, L.-C., Peng, Y.-H., Chang, H.-H., Hsu. T., Lu, C.-T., Huang, C.-H., Hsueh, C.-C., Kung, F.-C., Kuo, C.-C.*, Jiaang, W.-T.*, Wu, S.-Y.* Xanthine derivatives reveal an allosteric binding site in methylenetetrahydrofolate dehydrogenase 2 (MTHFD2). Journal of Medicinal Chemistry Aug 12; 64(15):11288-11301 (SCI; Category: Chemistry, Medicinal; Impact factor: 7.446; Ranking: 3/63, 4.8%, 2020 JCR) (*Corresponding author)
  4. Tang, Y.-C., Hsiao, J.-R., Jiang, S.-S., Chang, J.-Y., Chu, P.-Y., Liu, K.-J., Fang, H.-L., Lin, L.-M., Chen, H.-H., Huang, Y.-W., Chen, Y.-T., Tsai, F.-Y., Lin, S.-F., Chuang, Y.-J.*, Kuo, C.-C.* c-MYC-directed NRF2 drives malignant progression of head and neck cancer via glucose-6-phosphate dehydrogenase and transketolase activation. Theranostics 2021 Mar 11; 11(11):5232-5247 (SCI; Category: Medicine, Research & Experimental; Impact factor: 11.556; Ranking: 9/140, 6.4%, 2020 JCR) (*Corresponding author).
  5. Tsai, I.-T.#, Kuo, C.-C.#, Liou, J.-P., Chang, J.-Y.* Novel microtubule Inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. Journal of Biomedical Science 2018 Mar 28;25(1):28 (SCI; Category: Medicine, Research & Experimental; Impact factor: 5.203; Ranking: 20/136, 14.7%, 2018 JCR) (#First author).
  6. Lin, S.-Y., Yeh, T.-K., Song, J.-S., Hung, M.-S., Cheng, M.-F., Liao, F.-Y., Li, A.-S., Cheng, S.-Y., Lin, L.-M., Chiu, C.-H., Wu, M.-H., Lin, Y.-J., Hsiao, W., Sun, M., Wang, Y.-H., Huang, C.-H., Tang, Y.-C., Chang, H.-H., Huang, Z.-T., Chao, Y.-S., Shih, C., Pan, S.-L., Wu, S.-Y., Kuo, C.-C.*, Ueng, S.-H.* 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2, 3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy. Bioorganic Chemistry 2018 Feb 12; 77:600-607 (SCI; Category: Chemistry, Organic; Impact factor: 3.926; Ranking: 13/57, 22.8%, 2018 JCR) (*Corresponding author).
  7. Chen, H.-H., Chang, H.-H., Chang, J.-Y., Tang, Y.-C., Cheng, Y.-C., Lin, L.-M., Cheng, S.-Y., Huang, C.-H., Sun, M.-W., Chen, C.-T., Kuo, C.-C.* Enhanced B-Raf-mediated NRF2 gene transcription and HATs-mediated NRF2 protein acetylation contributes to ABCC1-mediated chemoresistance and glutathione-mediated survival in acquired topoisomerase II poison-resistant cancer cells. Free Radical Biology and Medicine 2017 Dec; 113:505-518 (SCI; Category: Biochemistry & Molecular Biology; Impact factor: 6.020; Ranking: 39/293, 13.3%, 2017 JCR) (*Corresponding author).
  8. Yeh, T.-K.#, Kuo, C.-C.#, Lee, Y.-Z. #, Ke, Y.-Y. #, Chu, K.-F. #, Hsu, H.-Y., Chang, H.-Y., Liu, Y.-W., Song, J.-S., Yang, C.-W., Lin, L.-M., Sun, M., Wu, S.-H., Kuo, P.-C., Shih, C., Chen, C.-T., Tsou, L.*, Lee, S.-J.* Design, synthesis, and evaluation of thiazolidine-2-4-dione derivatives as a novel class of glutaminase inhibitors. Journal of Medicinal Chemistry 2017 Jul 13;60(13):5599-612 (SCI; Category: Chemistry, Medicinal; Impact factor: 6.253; Ranking: 3/59, 5.1%, 2017 JCR) (#First author).
  9. Lin, S.-Y.#, Yeh, T.-K. #, Kuo, C.-C. #, Song, J.-S., Cheng, M.-F., Liao, F.-Y., Chao, M.-W., Huang, H.-L., Chen, Y.-L., Yang, C.-Y., Wu, M.-H., Hsieh, C.-L., Hsiao, W., Peng, Y.-H., Wu, J.-S., Lin, L.-M., Sun, M., Chao, Y.-S., Shih, C., Wu, S., Pan, S.-L.*, Hung, M.-S.*, Ueng, S.-H.* Phenyl benzenesulfonylhydrazides exhibit selective indoleamine 2,3-dioxygenase inhibition with potent in vivo pharmacodynamic activity and antitumor efficacy. Journal of Medicinal Chemistry 2016 Jan 14;59(1):419-30 (SCI; Category: Chemistry, Medicinal; Impact factor: 6.259; Ranking: 3/60, 5%, 2016 JCR) (# First author).
  10. Chang, K.-M., Chen, H.-H., Wang, T.-C., Chen, I.-L., Chen, Y.-T., Yang, S.-C., Chen, Y.-L., Chang, H.-H., Huang, C.-H., Chang, J.-Y., Shih, C., Kuo, C.-C.*, Tzeng, C.-C.* Novel oxime-bearing coumarin derivatives act as potent Nrf2/ARE activators in vitro and in mouse model. European Journal of Medicinal Chemistry 2015 Dec 1; 106:60-74 (SCI; Category: Chemistry, Medicinal; Impact factor: 3.902; Ranking: 6/59,10.2%, 2015 JCR) (*Corresponding author).
  11. Chen, H.-H., Wang, T.-C., Lee, Y.-C., Shen, P.-T., Chang, J.-Y., Yeh, T.-K., Huang, C.-H., Chang, H.-H., Cheng, S.-Y., Lin, C.-Y., Shih, C., Chen, C.-T., Liu, W.-M., Chen, C.-H., Kuo, C.-C.* Novel Nrf2/ARE activator, trans-coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38α/MAPKAPK-2 and PK-N3 signaling pathway. Chemical Research in Toxicology 2015 Sep 21;28(9):1681-92 (SCI; Category: Chemistry, Medicinal; Impact factor: 3.025; Ranking: 17/59, 28.8%, 2015 JCR) (*Corresponding author).
  12. Chen, S.-H.#, Kuo, C.-C.#, Li, C.-F., Cheung, C.-H., Tsou, T.-C., Chiang, H.-C., Yang, Y.-N., Chang, S.-L., Lin, L.-C., Pan, H.-Y., Chang, K.-Y., Chang, J.-Y.* O6-Methylguanine DNA methyltransferase repairs paltinum-DNA adducts following cisplatin treatment and predicts prognoses of nasopharyngeal carcinoma. International Journal of Cancer 2015 Sep;137(6):1291-305 (SCI; Category: Oncology; Impact factor: 5.531; Ranking: 29/213, 13.6%, 2015 JCR) (# First author).
  13. Chen, C.-C., Chu, C.-B., Liu, K.-J., Huang, C.-Y. F., Chang, J.-Y., Pan, W.-Y., Chen, H.-H., Chen, Y.-H., Lee, K.-D., Chen, M.-F., Kuo, C.-C.*, Chen, L.-T.* Gene expression profiling for analysis acquired oxaliplatin resistant factors in human gastric carcinoma TSGH-S3 cells: the role of IL-6 signaling and Nrf2/AKR1C axis identification. Biochemical Pharmacology 2013 Oct 1;86(7):872-87 (SCI; Category: Pharmacology & Pharmacy; Impact factor: 4.650; Ranking: 25/254, 9.8%, 2013 JCR) (*Corresponding author).
  14. Chen, H.-H., Chen, Y.-T., Huang, Y.-W., Tsai, H.-J., Kuo, C.-C.* 4-Ketopinoresinol, a novel naturally-occurring ARE activator, induces the Nrf2/HO-1 axis and protects against oxidative stress-induced cell injury via activation of PI3K/AKT signaling. Free Radical Biology and Medicine 2012 Mar 15;52(6):1054-66 (SCI; Category: Biochemistry & Molecular Biology; Impact factor: 5.271; Ranking: 52/290, 17.9%, 2012 JCR) (*Corresponding author).
  15. Chen, K.-L., Chang, W.-S.W., Cheung, C.H.A., Lin, C.-C., Huang, C.-C., Yang, Y.-N., Kuo, C.-P., Kuo, C.-C., Chang, Y.-H., Liu, K.-J., Wu, C.-M., Chang, J.-Y.* Targeting Cathepsin S induces tumor cell autophagy via the EGFR-ERK signaling pathway. Cancer Letters 2012 Apr 1;317(1):89-98 (SCI; Category: Oncology; Impact factor: 4.259; Ranking: 49/196, 25%, 2012 JCR).
  16. Lee, H.-Y., Chang, J.-Y., Nien, C.-Y., Kuo, C.-C., Shih, K.-H., Wu, C.-H., Chang, C.-Y., Lai, W.-Y., Liou, J.-P.* 5-Amino-2-aroylquinolines as highly potent tubulin polymerization inhibitors. Part 2 the impact of bridging groups at position C-2. Journal of Medicinal Chemistry 2011 Dec 22;54(24):8517-25 (SCI; Category: Chemistry, Medicinal; Impact factor: 5.248; Ranking: 3/59, 5.1%, 2011 JCR).
  17. Kuo, C.-C.*, Liu, T.-W., Chen, L.-T., Shiah, H.-S., Wu, C.-M., Cheng, Y.-T., Pan, W.-Y., Liu, J.-F., Chen, K.-L., Yang, Y.-N., Chen, S.-N., Chang, J.-Y.* Combination of arsenic trioxide and BCNU synergistically triggers redox–mediated autophagic cell death in human solid tumors. Free Radical Biology and Medicine 2011 Dec 15;51(12):2195-209 (SCI; Category: Biochemistry & Molecular Biology; Impact factor: 5.423; Ranking: 49/289, 16.9%, 2011 JCR) (*Corresponding author).

PATENTS

  1. Hsieh, H. P., Chang, J. Y., Kuo, C. C., Chao, Y. S. Coumarin Compounds and Their Use for Treating Cancer. US 8,058,427 B2. Patent duration: 2011/11/15 ~ 2029/6/10. USA (Granted)
  2. 謝興邦、張俊彥、郭靜娟、趙宇生。治療癌症之醫藥組合物。發明第I 415852號。專利權期間：2013/11/21 ~ 2029/06/10。中華民國。(已獲證)

Reference link

Comments are closed.